MedTrace Logo

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

NCT05145218 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 405

Last updated 2021-12-08

No results posted yet for this study

Summary

A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus weekly treatment with paclitaxel of recurrent platinum-resistant ovarian cancer.A total of 405 subjects will be enrolled.

Conditions

  • Recurrent Platinum-resistant Ovarian Cancer

Interventions

DRUG

Anlotinib Hydrochloride Capsules

Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.

DRUG

Paclitaxel injection

Paclitaxel is a novel anti-microtubule agent.

DRUG

TQB2450 injection

TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-28
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05145218 on ClinicalTrials.gov